HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Hepatitis E Clinical Trial

Official title:

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03282474
• Other study ID #: HepNet-SofE
• Secondary ID: 2017-000403-24
• Status: Completed
• Phase: Phase 2
• Start date: December 7, 2017
• Est. completion date: February 18, 2019

Study information

• Verified date: March 2019
• Source: Hannover Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm multicenter pilot study to provide preliminary evidence whether sofosbuvir (SOF) is efficacious and can be safely used in patients with chronic Hepatitis E virus infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 18, 2019
• Est. primary completion date: November 26, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent

2. Male or female, age = 18 years

3. Confirmation of chronic HEV infection documented by: Positive HEV RNA at least 3 months before Screening, and positive for HEV RNA at the time of Screening

4. Documented previous ribavirin therapy or documented contraindication for full dose (= 600mg qd) ribavirin monotherapy for at least 3 months

5. Body mass index (BMI) = 18 kg/m2

6. Screening ECG without clinically significant abnormalities

7. Subjects must have the following laboratory parameters at screening:

• Platelets = 60,000/µL

• INR =2.0 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR

• HbA1c = 10%

• Creatinine clearance (CLcr) = 30 mL/min, as calculated by the Cockcroft-Gault equation (using actual body weight)

8. Subject has not been treated with any investigational drug or device within 42 days of the Screening visit

9. A negative serum pregnancy test is required for female subjects (unless surgically sterile or women = 54 years of age with cessation for 24 = months of previously occurring menses).

Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not permitted.

Or

Consistent and correct use of 1 of the following methods of birth control listed below, in addition to a male partner who correctly uses a condom, from the date of Screening until 30 days after last dose of study drug:

• intrauterine device (IUD) with a failure rate of < 1% per year

• female barrier method: cervical cap or diaphragm with spermicidal agent

• tubal sterilization

• vasectomy in male partner

• hormone-containing contraceptive:

• implants of levonorgestrel

• injectable progesterone

• oral contraceptives (either combined or progesterone only)

• contraceptive vaginal ring

• transdermal contraceptive patch

10. Subject must be able to comply with the dosing instructions for study drug administration and be able to complete the study schedule of assessments.

Exclusion Criteria:

1. Clinically-significant illness (other than HEV) or any other major medical disorder that, in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol.

2. Ribavirin administration within the last 28 days.

3. Infection with the hepatitis C virus (defined as HCV RNA positive)

4. Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug (for example, gastric bypass or severe ulcerative colitis).

5. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.

6. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 2 years. Subjects with psychiatric illness that is wellcontrolled on a stable treatment regimen for at least 12 months prior to screening or has not required medication in the last 12 months may be included.

7. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

8. Pregnant or nursing female

9. Clinically-relevant drug or alcohol abuse within 12 months of screening including any uncontrolled drug use within 6 months of screening. A positive drug screen will exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator. Uncontrolled users of intravenous drugs will not be permitted to enroll in the study.

10. Use of any prohibited concomitant medications within 21 days of the Baseline/Day 1 visit.

Use of Amiodaron as concomitant medication is prohibited within 60 days of Baseline/Day1 visit.

11. Known hypersensitivity to SOF or formulation excipients.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis Chronic Viral
• Hepatitis E
• Hepatitis, Chronic

Intervention

Drug:
• Sofosbuvir
Sofosbuvir 400 MG Oral Tablet [Sovaldi]

Locations

Country	Name	City	State
Germany	Charité, Campus Virchow-Klinikum, Medical Department, Division of Hepatology and Gastroenterology	Berlin
Germany	University Medical Center Hamburg-Eppendorf, Center for Internal Medicine, I. Medical Clinic and Polyclinic	Hamburg
Germany	Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology	Hanover	Lower Saxony

Sponsors (4)

Lead Sponsor	Collaborator
Hannover Medical School	German Center for Infection Research, Gilead Sciences, HepNet Study House, German Liverfoundation

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects who become HEV RNA negative after 24 weeks of therapy	Measured by the proportion of subjects who become HEV RNA negative (HEV RNA undetectable)	after 24 weeks of therapy
Secondary	Proportion of subjects who are HEV RNA negative 12 weeks after discontinuation of therapy	Viral load measurement	12 weeks after discontinuation of therapy (week 36)
Secondary	Additional efficacy evaluations include HEV RNA change from baseline during therapy	Viral load and laboratory measurements	after 2 days, 4 days, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks,16 weeks, 20 weeks, and 24 weeks of therapy
Secondary	Comparison of proportion of patients who are HEV RNA negative after rapid or slow decline of HEV viral load after 24 weeks of therapy	Viral load measurement	after 24 weeks of therapy
Secondary	Proportion of subject who reached ALT normalization after 12 weeks and 24 weeks of therapy and 12 weeks after discontinuation of therapy	Laboratory measurement	after 12 and 24 weeks of therapy and 12 weeks after discontinuation of therapy (week 36)
Secondary	Assessment of safety: Adverse events and safety laboratory tests will be collected throughout the study	Collection of adverse events and safety laboratory tests	through study completion, an average of 36 weeks